LLY
902.74
-0.9%↓
UNH
596.8
+0.31%↑
NVO
131.05
+0.18%↑
JNJ
164.37
-0.29%↓
ABBV
193.18
+0.34%↑
LLY
902.74
-0.9%↓
UNH
596.8
+0.31%↑
NVO
131.05
+0.18%↑
JNJ
164.37
-0.29%↓
ABBV
193.18
+0.34%↑
LLY
902.74
-0.9%↓
UNH
596.8
+0.31%↑
NVO
131.05
+0.18%↑
JNJ
164.37
-0.29%↓
ABBV
193.18
+0.34%↑
LLY
902.74
-0.9%↓
UNH
596.8
+0.31%↑
NVO
131.05
+0.18%↑
JNJ
164.37
-0.29%↓
ABBV
193.18
+0.34%↑
LLY
902.74
-0.9%↓
UNH
596.8
+0.31%↑
NVO
131.05
+0.18%↑
JNJ
164.37
-0.29%↓
ABBV
193.18
+0.34%↑
Overview
Share price change
24h
Current
Min
82.94
Max
83.26
Recommendations | Strong Buy |
---|---|
12 Months Forecast | +6.27 upside |
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
82.46 / 87.21 Support & Resistance
AstraZeneca PLC ADR Chart
Related News
25 lip 2024, 09:17 UTC
AstraZeneca Raises Guidance After Results Beat Market Expectations -- Update
DJ
Read
25 lip 2024, 06:48 UTC
AstraZeneca Raises Guidance After Revenue, Earnings Beat Market Expectations
DJ
Read
12 lip 2024, 19:57 UTC
Instil Bio Shares Surge Following Rental Agreement with AstraZeneca
DJ
Read
5 wrz 2024, 13:00 UTC
China Detains AstraZeneca Employees Over Alleged Transport of Unapproved Drug -- WSJ
DJ
Read
29 lip 2024, 10:30 UTC
Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ
DJ
Read
25 lip 2024, 13:20 UTC
AstraZeneca Slides Despite Beating Quarterly Expectations And Hiking Its Outlook -- IBD
DJ
Read
25 lip 2024, 09:21 UTC
AstraZeneca's Guidance Lift Is Conservative; Risks to Upside -- Market Talk
DJ
Read
25 lip 2024, 07:05 UTC
AstraZeneca Guidance Raise Signals Portfolio Potential -- Market Talk
DJ
Read
25 lip 2024, 06:06 UTC
AstraZeneca Increased Interim Dividend by 7c to $1.00
DJ
Read
25 lip 2024, 06:04 UTC
AstraZeneca Had Seen Core EPS Grow by Low Double-Digit to Low Teens Percentage Range
DJ
Read
25 lip 2024, 06:04 UTC
AstraZeneca Had Seen Total Revenue Grow by Low Double-Digit to Low Teens Percentage Range
DJ
Read
25 lip 2024, 06:04 UTC
AstraZeneca Sees Core EPS Growth in 2024 by Mid Teens Percentage Range At Constant Currency
DJ
Read
25 lip 2024, 06:04 UTC
AstraZeneca Sees Total Revenue Growth in 2024 by Mid Teens Percentage Range At Constant Currency
DJ
Read
25 lip 2024, 06:03 UTC
AstraZeneca Raises 2024 View
DJ
Read
25 lip 2024, 06:02 UTC
AstraZeneca 2Q Revenue Consensus Was $12.7B
DJ
Read
25 lip 2024, 06:02 UTC
AstraZeneca 2Q Core EPS Consensus Was $1.95
DJ
Read
25 lip 2024, 06:00 UTC
AstraZeneca PLC 2Q Adj EPS $1.98
DJ
Read
25 lip 2024, 06:00 UTC
AstraZeneca PLC 2Q Pretax Pft $2.4B
DJ
Read
25 lip 2024, 06:00 UTC
AstraZeneca PLC 2Q Rev $12.94B
DJ
Read
25 lip 2024, 06:00 UTC
AstraZeneca PLC 2Q Oper Pft $2.75B
DJ
Read
25 lip 2024, 06:00 UTC
AstraZeneca PLC 2Q Net Pft $1.93B
DJ
Read
25 lip 2024, 06:00 UTC
AstraZeneca PLC 2Q EPS $1.24
DJ
Read
15 lip 2024, 06:04 UTC
AstraZeneca: Amolyt Pharma's Hldrs Eligible to Receive $250M On Achieving Specific Milestone
DJ
Read
15 lip 2024, 06:04 UTC
AstraZeneca: Amolyt Pharma's Hldrs Eligible to Receive $250M On Achieving Specific Milestone
DJ
Read
15 lip 2024, 06:02 UTC
AstraZeneca: Acquisition Includes $800M Upfront at Deal Closing
DJ
Read
15 lip 2024, 06:02 UTC
AstraZeneca: Amolyt Pharma's Total Consideration of Up to $1.05B
DJ
Read
15 lip 2024, 06:01 UTC
AstraZeneca: Acquisition Bolsters Alexion Rare Disease Late-Stage Pipeline
DJ
Read
15 lip 2024, 06:00 UTC
AstraZeneca Completes Acquisition of Amolyt Pharma
DJ
Read
15 lip 2024, 06:00 UTC
AstraZeneca PLC Acquisition of Amolyt Pharma completed
DJ
Read
15 lip 2024, 06:00 UTC
AstraZeneca PLC Acquisition of Amolyt Pharma completed
DJ
Read
Peer Comparison
Price change
AstraZeneca PLC ADR Forecast
Price Target
By TipRanks
12 Months Forecast
Average 88.26 USD 6.27%
High 99 USD
Low 74 USD
Based on 6 Wall Street analysts offering 12 month price targets forAstraZeneca PLC ADR - Dist in the last 3 months.
Rating Consensus
By TipRanks
Strong Buy
6 ratings
5
Buy
1
Hold
0
Sell
Based on 6 analysts giving stock ratings to AstraZeneca PLC ADR - Dist in the past 3 months.
Technical Score
By Trading Central
Short Term
Very Strong Bearish Evidence
Recent bearish events outweigh bullish events.
Intermediate Term
Bearish Evidence
Recent bearish events outweigh bullish events.
Long Term
No Evidence
There are no events.